Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. Novo Nordisk also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk A/S employs about 42,000 employees in 77 countries and markets its products in 170 countries. In 2016, Novo Nordisk A/S had revenue of DKK 111.7 billion.
Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its American Depository Receipts (ADRs) are listed on the New York Stock Exchange (NVO).